- Among kidney transplant recipients, cognitive performance improved significantly for both frail and nonfrail recipients by 3 months post-transplant.
- Between 1 and 4 years post-transplant, improvements plateaued among nonfrail recipients, whereas cognitive function declined among frail recipients.
Newswise — Washington, DC (January 24, 2019) — Among adults undergoing kidney transplantation, frailty was associated with cognitive decline over several years. The findings, which appear in an upcoming issue of the Journal of the American Society of Nephrology (JASN) suggest that efforts are needed to preserve cognitive function in frail kidney transplant recipients.
Lower kidney function is associated with worse cognitive function, but cognitive impairment is still present in many kidney transplant recipients after their kidney function is restored. Also, frailty—a decline in reserve and function across multiple physiologic systems that can cause physical and cognitive impairments— is a predictor of adverse outcomes in kidney transplant populations. It is unclear whether frail recipients experience post-transplant cognitive improvements.
To investigate, Nadia Chu, PhD, MPH (Johns Hopkins School of Medicine) and her colleagues under the guidance of senior author, Mara McAdams-DeMarco, PhD (Johns Hopkins Bloomberg School of Public Health), assessed pre-transplant frailty and cognitive function in 665 adult kidney transplant recipients, and they measured cognitive function up to 4 years post-transplant.
The team found that 15% of the patients were frail. After adjustments, pre-transplant cognitive scores were significantly lower among frail patients compared with nonfrail patients (89.0 vs. 90.8 on a scale of 0 to 100 with higher scores indicating better cognitive function). By 3 months post-transplant, cognitive performance improved significantly for both frail and nonfrail recipients. Between 1 and 4 years post-transplant, improvements plateaued among nonfrail recipients, whereas cognitive function declined among frail recipients. At 4 years post-transplant, cognitive scores were 5.5 points lower for frail recipients compared with nonfrail recipients.
“The great news is that, on average, everyone improved in cognitive function, regardless of age, sex, race, and frailty status in the short-term, likely as a result of the restoration of kidney function. But while non-frail recipients sustained their higher levels of cognitive function over the 4-year follow-up period, frail recipients actually began to deteriorate between 1-4 years post-kidney transplantation to levels that were on-average lower than their pre-kidney transplantation cognitive function,” said Dr. Chu. Dr. McAdams-DeMarco added that clinicians may consider regularly monitoring cognitive function after kidney transplantation. “Efforts to mitigate cognitive decline among frail kidney transplant candidates to prevent cognitive impairment and dementia–which has been found to be more common among kidney transplant recipients aged 55+ years than older adults generally—should begin within 1 year post-transplantation,” she said.
Study co-authors include Alden L. Gross, PhD, MHS, Ashton A. Shaffer, BA, Christine E. Haugen MD, Silas P. Norman, MD, Qian-Li Xue, PhD, A. Richey Sharrett, M.D., DrPH, Michelle Carlson, PhD, Karen Bandeen-Roche, PhD, Dorry L. Segev, M.D., PhD, and Mara A. McAdams-DeMarco, PhD.
Disclosures: This study was funded by the NIH, and the authors reported no financial disclosures.
The article, entitled “Frailty and Changes in Cognitive Function After Kidney Transplantation—Failure to Recover to Baseline Levels,” will appear online at http://jasn.asnjournals.org/ on January 24, 2019, doi: 10.1681/ASN.2018070726.
The content of this article does not reflect the views or opinions of The American Society of Nephrology (ASN). Responsibility for the information and views expressed therein lies entirely with the author(s). ASN does not offer medical advice. All content in ASN publications is for informational purposes only, and is not intended to cover all possible uses, directions, precautions, drug interactions, or adverse effects. This content should not be used during a medical emergency or for the diagnosis or treatment of any medical condition. Please consult your doctor or other qualified health care provider if you have any questions about a medical condition, or before taking any drug, changing your diet or commencing or discontinuing any course of treatment. Do not ignore or delay obtaining professional medical advice because of information accessed through ASN. Call 911 or your doctor for all medical emergencies.
Since 1966, ASN has been leading the fight to prevent, treat, and cure kidney diseases throughout the world by educating health professionals and scientists, advancing research and innovation, communicating new knowledge, and advocating for the highest quality care for patients. ASN has more than 20,000 members representing 131 countries. For more information, please visit www.asn-online.org or contact the society at 202-640-4660.
# # #